Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? (Q42470748)

1 November 2017

title

Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? (English)

1 reference

1 November 2017

1 reference

Cigolini M

1

1 reference

1 November 2017

Tonoli M

2

1 reference

1 November 2017

Borgato L

3

1 reference

1 November 2017

Frigotto L

4

1 reference

1 November 2017

Manzato F

5

1 reference

1 November 2017

Zeminian S

6

1 reference

1 November 2017

Cardinale C

7

1 reference

1 November 2017

Camin M

8

1 reference

1 November 2017

Chiaramonte E

9

1 reference

1 November 2017

De Sandre G

10

1 reference

1 November 2017

Lunardi C

11

1 reference

1 November 2017

publication date

1 March 1999

1 reference

1 November 2017

1 reference

1 November 2017

volume

143

1 reference

1 November 2017

issue

1

1 reference

1 November 2017

page(s)

81-90

1 reference

Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Abdominal fat distribution and disease: an overview of epidemiological data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: the European Fat Distribution Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Human adipose tissue in culture. VIII. Studies on the insulin-antagonistic effect of glucocorticoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

The regulation of tumor necrosis factor-alpha production in murine mast cells: pentoxifylline or dexamethasone inhibits IgE-dependent production of TNF-alpha by distinct mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900281-0

10.1016/S0021-9150(98)00281-0

7 January 2021

Identifiers

DOI

1 reference

release_qbddz2jbdfbrvbqhi22rcyomua

1 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qbddz2jbdfbrvbqhi22rcyomua

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference